Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 5
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 5
Join SI Premium – FREE
Stifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.
Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $145.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- TD Cowen Resumes Keyera Corp. (KEY:CN) (KEYUF) at Buy
- Morgan Stanley Upgrades Sonova Holding AG (SOON:SW) (SONVY) to Equalweight
Create E-mail Alert Related Categories
Analyst PT Change, New CoverageRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
